The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis

Charlotte G. Boone PharmD, Tony Antoniou PhD, David N. Juurlink MD PhD, Teagan Rolf von den Baumen BSc PharmD, Sophie A. Kitchen MSc, Georgia C. Richards BSc, Mina Tadrous PharmD PhD, Tara Gomes PhD

Abstract

Background: Low-dose codeine products can be purchased without a prescription in most of Canada. We explored trends in the purchasing of these products across the Canadian provinces from 2014 to 2019, evaluating the impact of Health Canada’s 2016 announcement of a proposed regulatory change and the 2017 opening of a 60-day public comment period, as well as the impact of Manitoba’s 2016 policy change requiring a prescription for the purchase of all codeine products in that province.

Methods: We evaluated population-adjusted monthly purchasing of codeine products from January 2014 to October 2019 using the IQVIA Canadian Drug Store and Hospital Purchases Audit database, stratified by province and over-the-counter (OTC) status. The primary outcomes were change in the monthly volume of low-dose codeine purchased after the 2016 federal regulatory proposal and the 2017 period of public comment across the provinces. Our secondary analysis was the impact of Manitoba’s policy change in February 2016 requiring a prescription for low-dose codeine. We conducted a time-series analysis using interventional autoregressive integrated moving average models.

Results: Over the study period, 24,120 kg of codeine (3.025 billion units) and 937,867 kg of acetaminophen were sold as OTC, low-dose codeine products across the Canadian provinces. Health Canada’s 2016 announcement did not significantly affect OTC codeine purchasing ($p = 0.57$). The initiation of a 60-day public comment period was associated with a roughly 44% decrease in OTC codeine purchasing ($p = 0.03$). In Manitoba, purchasing of the same codeine formulations decreased after rescheduling in February 2016 ($p < 0.001$). We observed no significant change in the rate of purchasing of higher dose codeine formulations in response to scheduling changes in Manitoba ($p = 0.22$).

Interpretation: Although Health Canada’s 2016 announcement of a proposed regulatory change did not appear to have an effect on OTC codeine purchasing nationally, the 60-day public comment period was associated with a decrease in purchasing. Further, Manitoba’s 2016 policy change was associated with a significant and sustained decrease in the overall volume of codeine purchased. Given the potential risks of codeine dependence and acetaminophen toxicity with these products, a national rescheduling strategy should be considered.

In Canada, the opioid crisis has affected every region of the country. Recently, all provinces (excluding Quebec) have made efforts to monitor opioid prescribing through implementation of prescription monitoring programs. However, purchases of over-the-counter (OTC), low-dose codeine products are not accounted for in these systems. Although codeine is available only by prescription in many countries, low-strength products are available OTC in the United Kingdom, Canada and Ireland, among others. The accessibility of OTC codeine formulations reinforces the perception of safety that can contribute to hazardous use, dependence and other harms, including from the acetylsalicylic acid or acetaminophen with which the codeine is combined.

In Canada, The Controlled Drugs and Substances Act defines OTC (Schedule II) codeine preparations as those containing no more than 8 mg or its equivalent of codeine phosphate per unit of solid form, or no more than 20 mg codeine phosphate per 30 mL of liquid preparation. Additionally, these products must contain 2 or more additional medicinal ingredients of specified quantities. The most commonly sold OTC codeine

Competing interests: Georgia Richards reports support from the National Institute for Health Research School for Primary Care Research, the Naji Foundation and the Rotary Foundation during the conduct of the study, outside the submitted work. No other competing interests were declared.

This article has been peer reviewed.

Correspondence to: Tara Gomes, tara.gomes@unityhealth.to

CMAJ Open 2021 December 14. DOI:10.9778/cmajo.20210173

© 2021 CMA Joule Inc. or its licensors
preparations in Canada contain codeine, acetaminophen and caffeine. Although intended to prevent inappropriate use, the requirement for OTC codeine products to be combined with other medicinal ingredients places consumers at risk of toxicity from these drugs, in addition to opioid-related harm, particularly hepatotoxicity caused by acetaminophen.11,12

In Canada, the federal government is responsible for determining the conditions of sale of drug products, such as the requirement for a prescription. Provincial and territorial governments can specify additional conditions of sale, but those conditions must be more restrictive than federal legislation.13 On Feb. 1, 2016, the College of Pharmacists of Manitoba mandated that all low-dose codeine preparations previously considered OTC would require a prescription by a pharmacist or other prescriber.13 Similar regulatory proposals and policy changes on patterns of use, as well as the impact of Manitoba’s 2016 policy change requiring a prescription for low-dose codeine. We explored trends in the purchasing of low-dose codeine products across the Canadian provinces from 2014 to 2019, evaluating the impact of federal regulatory proposals on patterns of use, as well as the impact of Manitoba’s 2016 policy change requiring a prescription for the purchase of codeine products in that province.

Methods

Study design and setting
We conducted a population-based, time-series analysis of low-dose codeine purchasing by pharmacies and hospitals across the Canadian provinces from Jan. 1, 2014, to Oct. 31, 2019. Data regarding codeine consumption in the Canadian territories were not available for this analysis.

Data sources
We used the IQVIA Canadian Drug Store and Hospital Purchases Audit (CDH) database during the study period. IQVIA’s CDH is a projected audit. Sampling covers over one-third of all retail pharmacies (about 3000 pharmacies) and 88% of hospitals (about 800 hospital sector outlets) in Canada. Data are subsequently stratified by size, region and outlet type, and total market volume is then projected for each product by region. Within the drug store and retail sector, projections for 98% of products fall within 12.5% of their true activity at the national level. Based on the previous 72 months (ending April 2021), 99% of all codeine-related purchases (including OTC products) came from retail pharmacies (J. Gaudet, IQVIA, Kirkland, Que.: personal communication, 2021). We used annual population estimates from Statistics Canada for 2014 to 2019 to adjust consumption rates in each province to its population.20

Outcomes
Our primary outcomes were the change in monthly volume of low-dose codeine purchased after the federal regulatory proposal regarding a change to prescription-only status and the subsequent 60-day period of public comment across the Canadian provinces. For this analysis, we excluded data from Manitoba because low-dose codeine products were rescheduled as prescription-only during the study period. The volume of dispensed low-dose codeine “units” allowed for standardization between liquid and solid dosage forms. We defined 1 unit as 8 mg of codeine, the standard dose in 1 OTC tablet.

In a secondary analysis, we investigated the impact of Manitoba’s policy change in February 2016, requiring a prescription for low-dose codeine. We evaluated several measures, including the monthly purchasing volume of low-dose codeine products, higher-dose codeine products (which have always required a prescription) and all codeine products combined. We sought to determine whether restrictions on the sale of OTC codeine products were associated with a compensatory increase in the use of higher-dose codeine products.

Statistical analysis
We used interventional autoregressive integrated moving average (ARIMA) models to evaluate the impact of regulatory proposals and policy changes on monthly purchasing of codeine at a population-adjusted rate in Canadian provinces. We differenced the time series and used the augmented Dickey–Fuller test to confirm stationarity. We selected model parameters using the residual autocorrelation function (ACF), partial ACF, and inverse ACF correlograms. We chose the final model using the autocorrelation plots, the Ljung–Box $\chi^2$ test for white noise and the $R^2$ estimate of fit. In the primary analysis, we modelled Health Canada’s proposed regulatory changes (July 2016) and the opening of the 60-day public comment period on these regulatory changes (September 2017) as ramp functions to test for gradual changes in trends.

In our secondary analysis of codeine purchasing in Manitoba, we analyzed the impact of the February 2016 scheduling change on monthly sales of codeine-containing products. In separate models, we used a step intervention function to test for an immediate change in total codeine purchasing and in low-dose codeine purchasing, and a ramp intervention function to test for a gradual slope change in purchasing of higher-dose codeine products. We completed all analyses using SAS Enterprise Guide version 9.4 and the SAS/ETS Time Series Forecasting System.

Ethics approval
Given the aggregate nature of the source data, research ethics approval was not required.
Results

From January 2014 to October 2019, 24,120 kg of codeine (3.025 billion units), together with 937,867 kg of acetaminophen, were sold as OTC, low-dose codeine products across the Canadian provinces. After population adjustment, this amounts to about 88 codeine tablets dispensed OTC for every resident of the Canadian provinces over a period of about 5 years, or roughly 18 tablets per resident per year.

Impact of selected opioid policies and interventions

In our primary analysis of low-dose codeine purchasing across the Canadian provinces, we found that the proposed regulatory change announced in 2016 was not significantly associated with low-dose codeine purchasing (ramp function $p = 0.574$). In contrast, the subsequent announcement of a 60-day comment period in September 2017 was associated with a 43.5% decrease in low-dose codeine purchasing, from 1.38 units per resident in August 2017 to 0.78 units in October 2019 (ramp function $p = 0.03$) (Figure 1; Appendix 1, available at www.cmajopen.ca/content/9/4/E1181/suppl/DC1).

In the secondary analysis of Manitoba trends, the February 2016 policy change was associated with an immediate 92.3% reduction in purchasing of low-dose codeine products by step function, from 3.50 units per resident in January 2016 to 0.27 units in February 2016 (step function $p < 0.001$) (Figure 2, Appendix 1). The scheduling change was not associated with compensatory changes in purchasing of higher-dose prescription codeine formulations (ramp function $p = 0.22$; Figure 2, Appendix 1) and was associated with a significant decrease in overall codeine purchasing (step function $p < 0.001$; Figure 2, Appendix 1).

Cross-provincial comparison of low-dose codeine purchasing

In the final year of our study period (Nov. 1, 2018, to Oct. 31, 2019), 375,847,016 units of low-dose codeine preparations were sold across the provinces, including Manitoba, representing 3007 kg of codeine and 114,703 kg of acetaminophen. In Manitoba, where codeine products were available only with a prescription for this period, low-dose products accounted for 3.3% of all codeine sold by weight, compared with 21.7% overall in all Canadian provinces, whereby all other provinces have low-dose codeine products available for OTC sale (Table 1). We identified considerable interprovincial variability in the rate of OTC codeine purchasing, from 1.6 units per person in Quebec to 17.3 units per person in British Columbia. The percentage of codeine attributable to low-dose preparations also varied by province, from 6.9% of all codeine purchased in Alberta to 44.6% of all codeine purchased in Ontario.

Figure 1: Low-dose codeine purchasing, in units per resident per month (1 unit = 8 mg), among the Canadian provinces from January 2014 to October 2019. Vertical bars indicate policy changes. Note: A = Health Canada’s proposal of regulatory changes on July 17, 2016; B = Health Canada’s 60-day public commenting period opened on Sept. 9, 2017.
Interpretation

In this population-based time-series analysis, we found that more than 375 million low-dose codeine tablets were dispensed without a prescription in Canada in the most recent 1-year period of the study, from Nov. 1, 2018, to Oct. 31, 2019. This represents about 10 tablets sold for every resident within Canada’s provinces; over one-fifth of all codeine dispensed (by weight) in the Canadian provinces was sold without a prescription. Although we observed interprovincial variation in OTC codeine dispensing across Canada, these trends were consistent with patterns of prescription opioid dispensing that have been reported previously, which suggests relatively strong alignment between regional patterns of OTC and prescription opioid use across the country.20,21 Interestingly, although the announcement of proposed national regulatory changes to OTC codeine products had no impact on OTC codeine accessibility, the initiation of a public commenting period was associated with reduced purchasing. In addition, rescheduling of low-dose codeine products in Manitoba was associated with an immediate and striking decrease in the total volume of these products sold, with no compensatory increase in higher-dose prescription codeine purchasing, and a significant decrease in the overall volume of codeine purchased. This shows the potential impact of rescheduling in Canada, if applied nationally.

The decrease in codeine purchasing observed after the opening of a comment period suggests that the engagement of stakeholders in regulatory discussion influenced consumption trends. This may indicate that media coverage22 and communication to clinicians regarding the potential regulatory changes from their college23 increased public awareness of the potential risks of codeine, and may have influenced consumption trends and pharmacist counselling. The observed reduction in sales of low-dose codeine products is suggestive of a therapeutic area in which consumers and health care providers are willing to consider alternative therapies. Ongoing policy discussions should consider this as an indication of the ability for pharmacists and patients to adapt to changing regulation around these products, if introduced nationally.

This is further reinforced by our findings in Manitoba, which are consistent with a study that evaluated the 2018 rescheduling of low-dose codeine in Australia.24 In both of these studies, purchasing of low-dose codeine preparations declined immediately after the policy change, with no compensatory change in purchasing of high-dose formulations. The consistency of these findings suggests that rescheduling low-dose codeine preparations may reduce potentially unsafe use of these products without shifts in treatment toward higher-strength alternatives.

It is also important to consider how changes in analgesic availability, in the absence of improved access to other pain

Figure 2: Purchasing of over-the-counter (low-dose), prescription-strength codeine products, and total codeine purchased, in units per resident per month (1 unit = 8 mg) in Manitoba from January 2014 to October 2019. Vertical bar indicates policy change on Feb. 1, 2016, which required a prescription for all codeine products, regardless of strength.
management modalities, can lead to unintended consequences, such as a corresponding shift to other, potentially less safe alternatives, both prescribed and nonprescribed. In Australia, the rescheduling of codeine products led to significant increases in non opioid OTC analgesic use, suggesting that, in some patients, safer approaches were used to manage pain. However, more data are needed to determine the degree to which patients who were previously accessing OTC codeine were able to successfully manage their pain with nonopioid analgesics, or whether they transitioned to more potent opioids. Although it is reassuring that the 2018 rescheduling in Australia resulted in an abrupt decrease in monthly codeine-related poisonings (as captured by calls to the New South Wales Poisons Information Centre), future work should explore whether Manitoba’s regulatory change led to any patient harm, including potential switches from prescription codeine to the unregulated opioid supply. This work could identify important opportunities for clinicians and policy-makers to support patients who are currently accessing OTC codeine through a transition in therapy if regulatory changes are expanded further across Canada.

**Limitations**

The data used in our study represent codeine purchasing by pharmacies, and may not be reflective of consumption patterns, as products may expire and be discarded, or be purchased by an individual and not completely consumed. However, pharmaceutical purchasing analysis methods are often used in antimicrobial stewardship analyses, as they strongly correlate with consumption patterns, and such data are likely to provide an estimate of community consumption.

Table 1: Descriptive characteristics for provincial sales of low-dose codeine products between November 2018 and October 2019

<table>
<thead>
<tr>
<th>Province</th>
<th>Units of codeine*</th>
<th>Codeine sales</th>
<th>Acetaminophen sales</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. of units</td>
<td>Rate, units per resident</td>
<td>% of total codeine sold as OTC†</td>
</tr>
<tr>
<td>Alberta</td>
<td>17 688 955</td>
<td>4.0</td>
<td>6.9</td>
</tr>
<tr>
<td>British Columbia</td>
<td>89 681 975</td>
<td>17.7</td>
<td>38.0</td>
</tr>
<tr>
<td>Manitoba</td>
<td>2 175 128</td>
<td>11.6</td>
<td>3.3</td>
</tr>
<tr>
<td>New Brunswick</td>
<td>5 836 590</td>
<td>7.5</td>
<td>21.5</td>
</tr>
<tr>
<td>Nova Scotia</td>
<td>14 369 659</td>
<td>14.8</td>
<td>40.5</td>
</tr>
<tr>
<td>Ontario</td>
<td>225 685 892</td>
<td>15.5</td>
<td>44.6</td>
</tr>
<tr>
<td>Prince Edward Island, Newfoundland and Labrador</td>
<td>3 853 873</td>
<td>5.7</td>
<td>11.9</td>
</tr>
<tr>
<td>Quebec</td>
<td>13 570 422</td>
<td>1.6</td>
<td>19.3</td>
</tr>
<tr>
<td>Saskatchewan</td>
<td>2 984 521</td>
<td>2.5</td>
<td>9.3</td>
</tr>
<tr>
<td>All provinces</td>
<td>375 847 016‡</td>
<td>10.0</td>
<td>21.7</td>
</tr>
</tbody>
</table>

Note: OTC = over-the-counter.
*1 unit = 8 mg.
†Reported as a percent of total mass of codeine sold.
‡If the dosage form was not sold in 8 mg units, we converted the volume to these standard units. Therefore, the provincial total does not equal the sum of provinces because of rounding error.
§Weights have been rounded to the nearest kilogram.
Conclusion

Despite a trend toward lower use over time, the overall volume of low-dose codeine purchasing by pharmacies remains high, with an annual rate of 10 tablets purchased by pharmacies for every resident of the Canadian provinces in 2019. Manitoba’s rescheduling of these products in 2016 shows the potential for rapid, large decreases in low-dose codeine purchasing across Canada if such a change were implemented nationally. Given the risks of medication-related harm and dependence associated with low-dose codeine products, there is an opportunity for federal regulatory changes to improve medication safety across Canada.

References


Contributors: All authors made substantial contributions to the conception and design of the work. Charlotte Boone and Tara Gomes were responsible for data analysis. All authors contributed to data interpretation. Charlotte Boone and Tara Gomes drafted the work, and all other authors revised it critically for important intellectual content. All authors provided final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding: This study was funded by grants from the Ontario Ministry of Health and the Canadian Institutes for Health Research.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

Data sharing: The authors are unable to share the underlying data because of data sharing agreements; however, these data can be purchased from IQVIA. More information is available at www.iqvia.com.

Acknowledgement: The authors thank IQVIA for the use of its Canadian Drugstore and Hospital Purchases Audit.

Disclaimer: The statements, findings, conclusions, views and opinions expressed in this report are based in part on data obtained under licence from IQVIA Solutions Canada Inc., concerning the following information services: CDH, data period Nov. 1, 2013, to Oct. 31, 2019. All rights reserved. The statements, findings, conclusions, views and opinions expressed herein are not necessarily those of IQVIA Inc. or any of its affiliated or subsidiary entities.

Supplemental information: For reviewer comments and the original submission of this manuscript, please see www.cmajopen.ca/content/9/4/E1186/suppl/DC1.